| scholarly article | Q13442814 |
| P50 | author | Sakae Tanaka | Q39065998 |
| P2093 | author name string | Sakae Tanaka | |
| P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
| Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone | Q28241025 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin | Q28261537 | ||
| Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab | Q28265584 | ||
| Romosozumab Treatment in Postmenopausal Women with Osteoporosis | Q28278665 | ||
| NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference | Q74145388 | ||
| Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system | Q28283972 | ||
| WNT signaling in bone homeostasis and disease: from human mutations to treatments | Q28285090 | ||
| The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone | Q28393372 | ||
| Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. | Q34107428 | ||
| Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients | Q34346682 | ||
| Osteoporosis in the European Union: a compendium of country-specific reports | Q34376780 | ||
| Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling | Q34384039 | ||
| Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial | Q34537630 | ||
| Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts | Q34679499 | ||
| Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice | Q35156214 | ||
| Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. | Q35635751 | ||
| New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide | Q35755175 | ||
| Effects of Deletion of ERα in Osteoblast-Lineage Cells on Bone Mass and Adaptation to Mechanical Loading Differ in Female and Male Mice | Q35864023 | ||
| Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling | Q36431762 | ||
| Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual | Q36497298 | ||
| Mechanisms of anabolic therapies for osteoporosis | Q36924676 | ||
| HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis | Q37236532 | ||
| Adverse effects of bisphosphonates: implications for osteoporosis management | Q37246255 | ||
| Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EF | Q37432186 | ||
| Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis | Q37581507 | ||
| New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. | Q37748586 | ||
| Biochemical and molecular mechanisms of action of bisphosphonates. | Q37812800 | ||
| Efficacy and safety of currently marketed anti-osteoporosis medications. | Q38272390 | ||
| Short-term and long-term effects of osteoporosis therapies. | Q38473594 | ||
| Role and mechanism of action of sclerostin in bone | Q38807230 | ||
| Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. | Q40004851 | ||
| Remodeling- and Modeling-Based Bone Formation with Teriparatide versus Denosumab: A Longitudinal Analysis from Baseline to 3 Months in the AVA Study | Q42696517 | ||
| Antiapoptotic molecule Bcl-2 is essential for the anabolic activity of parathyroid hormone in bone | Q46296752 | ||
| The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review. | Q47386961 | ||
| The effect of switching from teriparatide to anti-RANKL antibody on cancellous and cortical bone in ovariectomized mice | Q47595884 | ||
| Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. | Q47823018 | ||
| RANKL: A therapeutic target for bone destruction in rheumatoid arthritis | Q50207113 | ||
| Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. | Q54562620 | ||
| Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis | Q73794664 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | teriparatide | Q411781 |
| Romosozumab | Q7363297 | ||
| P304 | page(s) | 158-164 | |
| P577 | publication date | 2019-04-29 | |
| P1433 | published in | EFORT Open Reviews | Q39053387 |
| P1476 | title | Molecular understanding of pharmacological treatment of osteoporosis | |
| P478 | volume | 4 |
| Q90152614 | The Antiosteoporosis Effects of Yishen Bugu Ye Based on Its Regulation on the Differentiation of Osteoblast and Osteoclast | cites work | P2860 |
Search more.